

**Reference Number:** FOI202223/464  
**From:** Commercial  
**Date:** 14 December 2022  
**Subject:** Incidence and treatment of clotting disorders

Could you please provide answers to the following three questions related to the incidence and treatment of clotting disorders:

Q1 How many patients has your trust treated (for any medical condition) in the past 3 months with the following drugs:

- a. Alphanate
- b. Alprolix
- c. BeneFIX
- d. HaemateP
- e. Idelvion
- f. Refixia
- g. Rixubis
- h. Veyvondi
- i. Voncento
- j. Wilate
- k. Willfact

Q2 How many patients have been treated in the past 3 months with:

- a. Gene therapy for Haemophilia B ONLY
- b. Desmopressin for Von Willebrand Disease ONLY
- c. Tranexamic Acid for Von Willebrand Disease ONLY

Q3 Of the patients that were treated with Veyvondi in the past 3 months, how many patients received treatment:

- a. During surgery
- b. On demand to treat bleeding episodes

A1 - Information not held – the Trust does not routinely collate or hold this information centrally  
A3 as part of its management or performance data. In order to confirm treatment following medication being dispensed, the Trust would be required to access personal data of the individuals and as such the data is exempt under Section 40: Personal data.